



As one of the metabolic disorders that induce chronic liver 
diseases, non‑alcoholic fatty liver disease (NAFLD) currently 
attracts more attention than in the past decades. Although it is 
considered as a relatively benign form of chronic liver injury, 
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ABSTRACT
Non‑alcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver injury across the world. It is also strongly 
related to other pathological conditions, including obesity, diabetes, cardiovascular diseases, and symptoms of metabolic syndrome. 
Pathogenesis of NAFLD remains not fully characterized but is generally attributed to the occurrence of insulin resistance, lipid metabolism 
dysfunction, oxidative stress, inflammation, and necro‑apoptosis. Every potential therapeutic strategy should target one or some of these 
pathological events in the liver. Over the past decades, application of herbal treatment for NAFLD has received increasing attention 
due to its wide availability, low side effects, and proven therapeutic mechanisms and benefits. In recent years, some monomers and 
certain functional mixtures of herbs have been extensively examined for their potential uses in NAFLD treatment. In the present review, 
we selected several herbal derivatives under intense basic and/or clinical investigations by carrying out a PubMed search of English 
language articles relevant to herbal derivatives and NAFLD, such as polysaccharide portion of wolfberry, garlic‑derived monomers, 
red grape–derived resveratrol, and milk thistle–derived substances. They have been shown to target the pathological events during 
NAFLD initiation and progression both in pre‑clinical studies and clinical trials. Although more detailed mechanistic researches and 
long‑term clinical evaluations are needed for their future applications, they offer unanticipated and great health benefits without obvious 
adverse effects in NAFLD therapy.
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about 20% of NAFLD patients could progress to cirrhosis and liver 
cancer, if not successfully retarded or reversed. Unlike alcoholic 
fatty liver disease (AFLD), NAFLD is not induced by the abuse 
or over‑consumption of alcohol (below 30 g alcohol/day for men 
and 20 g alcohol/day for women).[1] NAFLD is classified into 
four types according to the severity: Type 1 NAFLD is defined 
by steatosis with no inflammation or fibrosis; Type 2 NAFLD is 
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steatosis with non‑specific lobular inflammation but absence of 
fibrosis or hepatocyte ballooning; Type 3 NAFLD is steatosis 
with inflammation and fibrosis of variable levels [non‑alcoholic 
steatohepatitis (NASH)]; Type 4 NAFLD is steatosis with inflam‑
mation, hepatocyte ballooning, and fibrosis or Mallory‑Denk 
bodies (NASH).[2‑4]
Epidemiology
NAFLD is one of the leading causes of chronic liver disease 
in both developed and developing countries. In a study of adult 
NAFLD prevalence based on histological aspects, steatosis was 
present in ~70% of obese individuals and ~ 35% of lean individu‑
als. NASH was found in ~18.5% of obese people and ~2.7% of 
lean people. The differences in these two sets of population are 
significant.[5] Several population‑based studies found that the 
prevalence of fatty liver is 13‑22% in lean non‑alcoholic subjects 
by using ultrasound imaging as the diagnostic method.[6‑8] In 
the Western world, NAFLD affects 20‑35% of adult people and 
5‑17% of children.[9,10] Due to the content of fat in modern diet 
and change in the people’s lifestyle, NAFLD has become one of 
the leading causes of chronic liver diseases in China (~15%)[11] 
and Hong Kong (~27.3%).[12]
It is well known that NAFLD shows gender and age differences 
in normal population. According to a recent survey in Japan, con‑
cerning cirrhotic NASH patients, the prevalence in women (~57%) 
was higher than in men (~43%).[13] However, another survey that 
investigated the prevalence of hepatocellular carcinoma in already 
established NASH patients found that men exhibited higher 
prevalence (~62%) when compared with women (~38%).[14] The 
causes of gender differentiation of NAFLD may be attributed to 
estrogenic endocrinology, fat distribution, and lifestyle differ‑
ences (e.g., smoking population ratio is higher in men than in 
women). However, the details of the reason and mechanism of 
gender differentiation remain one of the unresolved questions in 
the field of hepatology.
Prevalence of NAFLD is also influenced by ethnicity. Afri‑
can‑Americans show significantly less hepatic steatosis, although 
the prevalence of obesity and diabetes is relatively high.[3] 
Hispanic‑Americans exhibit high prevalence of steatosis, while 
Asian‑Americans only show an intermediate level of prevalence 
of steatosis.[9,15] Another study found that liver dysfunction in 
Japanese with severe obesity [body mass index >35 kg/m2] tends 
to be more severe than that in non‑Japanese patients.[16] Differ‑
ences of NAFLD prevalence are associated with different visceral 
adiposity and metabolic responses.
Pathological mechanisms
During the past two decades, although some cellular processes 
of NAFLD have been extensively studied, the exact pathogenesis 
of NAFLD remains largely unknown. Few years ago, a patho‑
logical model of NAFLD named “multi‑hit” model described the 
pathological mechanisms of NAFLD initiation and progression.[17] 
In this model, the first hit in NAFLD is the dysfunction of fatty acid 
metabolism which leads to insulin resistance and altered signaling 
transductions, thereby making the hepatocytes vulnerable to the 
following multiple hits. Mitochondrial fatty acid oxidation which 
induces oxidative stress, expression of pro‑inflammatory cytokines 
and chemokines that is nuclear factor kappa B (NF‑κB) depen‑
dent, expression of pro‑fibrogenic factors, and adipocytokines are 
considered as the possible causative factors that contribute to cell 
inflammation and necrosis/apoptosis with subsequent activation of 
fibrogenic cascade.[17,18] Detailed pathogenic events in the initiation 
and development of NAFLD are summarized in Figure 1. Very 
recently, the “multi‑hit” model has been amended to a “multiple 
parallel hit” model in which steatosis and NASH are discrete enti‑
ties rather than two points of the NAFLD spectrum, not only from 
a histological but also from a pathophysiological standpoint.[19,20]
Current therapies
To date, there are two major categories of NAFLD thera‑
pies: (1) lifestyle interventions (including weight reduction, di‑
etary modification, and physical exercise) and (2) pharmaceutical 
therapies. Weight reduction and dietary modification are the most 
recognized strategies for the control of NAFLD. In recent years, 
emerging evidence suggests that long‑term and moderate‑intensity 
exercise is a very effective and safe way to retard the progres‑
sion of not only NAFLD but also some other kinds of metabolic 
diseases, including obesity and hyperlipidemia. However, the 
underlying mechanisms of lifestyle interventions in attenuating the 
progression of NAFLD still remains largely unknown, although a 
large number of clinical studies have confirmed their therapeutic 
potentials. For pharmaceutical therapies, a wide range of drugs, 
including antioxidants, insulin sensitizers, lipid lowering agents, 
and renin–angiotensin system blockers, have been applied in clini‑
cal trials. However, pharmaceutical therapies for NAFLD exhib‑
ited few positive outcomes in clinical trials, although animal and 
Figure 1. Illustration of molecular events involved in the pathogenesis of 
non‑alcoholic fatty liver disease
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cellular studies contributed several promising advancements.[21,22]
In recent years, the beneficial effects of herbal derivatives on 
NAFLD progression have received increasing attention since these 
substances hold several advantages: (1) widely available around 
the world, particularly in Chinese societies; (2) natural products 
with low or minimal side effects; and (3) some of them have been 
extensively studied in modern basic and clinical studies.[23] In the 
current review, we mainly focus on the recent advances of herbal 
derivatives in the amelioration of NAFLD in laboratory studies 
and, if applicable, clinical trials.
RECENT FINDINGS FROM HERBAL 
TREATMENT OF NAFLD
Lycii fructus (枸杞子 Gǒu Qǐ Zǐ, wolfberry, goji berry)
Wolfberry is the fruit of plant Lycium barbarum of the fam‑
ily Solanaceae. It is a famous drug or supplement in traditional 
Chinese medicine in which it holds beneficial properties on both 
liver and eyes.[24] In terms of substances, the polysaccharide portion 
of wolfberry (often referred as LBP) represents the most important 
part. Modern studies indicate that LBP possesses a wide range of 
biological actions, including antioxidant effect, immunoregulation, 
neuroprotection, control of glucose metabolism, and anti‑tumor 
activities. Clinical trials also found that intake of LBP juice in‑
creases the number of lymphocytes and levels of interleukin‑2 
and immunoglobulin G in human beings. LBP also was found to 
increase the serum levels of antioxidants while decreasing the lipid 
peroxide formation.[25,26] In the liver, early reports demonstrated 
that treatment with LBP inhibited proliferation and induced apop‑
tosis in hepatoma cells, leading to possible anti‑tumor application 
of LBP.[27,28] Another study exhibited the protective effects of LBP 
on high‑fat diet induced liver oxidative stress injury through the 
restoration of antioxidant enzyme activities and the reduction of 
oxidative stress products [e.g. malondialdehyde (MDA)].[29] In 
an alcohol‑induced liver injury rat model, LBP co‑treatment with 
the administration of ethanol significantly ameliorated the liver 
injury. Underlying mechanism involved alleviation of oxidative 
stress and reduction of lipid accumulation in the liver.[30] We also 
found that in a carbon tetrachloride (CCl4)‑induced acute mouse 
liver injury model, pre‑treatment with 1 mg/kg and 10 mg/kg LBP 
before the intoxication of CCl4 obviously improved hepatic his‑
tology, reduced oxidative stress, alleviated hepatic inflammation/
chemoattraction, and promoted liver regeneration partly through 
an NF‑κB–dependent pathway.[31] Due to its beneficial properties 
in the amelioration of oxidative stress and inflammation, it is rea‑
sonable to speculate its role in NAFLD progression. To test this 
hypothesis, we applied our newly established voluntary NAFLD 
rat in which the energy percentage from the fat is only 30% to 
co‑treat with LBP.[32] Eight‑week induction of NAFLD in the rat 
introduced typical clinical symptoms of fatty liver disease, such 
as fat deposition, fibrosis, increased serum aminotransferase level, 
oxidative stress, inflammation, and apoptosis. Co‑treatment with 
LBP (1 mg/kg, daily oral feeding) effectively improved hepatic 
histology, reduced fat accumulation, fibrosis, oxidative stress, 
inflammation, and apoptosis partially through modulating the 
transcriptional factors NF‑κB and activator protein‑1 (AP‑1). In 
addition, long‑term uptake of LBP did not show obvious adverse 
effect on healthy rat liver (Xiao et al., submitted manuscript). 
Therefore, we concluded that LBP holds great potential in the 
treatment of NAFLD with low side effects.
Garlic (大蒜 Dà Suàn)
Garlic, or Allium sativum, is a species in the onion genus 
Allium. It has a very long history (over 6,000 years) as both culinary 
and medicinal uses in Asia, Egypt, and the Mediterranean regions. 
In terms of liver diseases, a recent paper reported the protective 
effect of oral consumption of whole garlic attenuates high‑fat 
diet caused abnormal lipid profile through AMP‑activated protein 
kinase (AMPK) pathway.[33] In a fructose‑fed rat model, admin‑
istration of raw garlic homogenate along with the diet induction 
improves insulin resistance, oxidative stress, and lipid metabo‑
lism.[34] Aged black garlic, when given along with chronic ethanol 
administration in Sprague‑Dawley rat, effectively reduced hepatic 
oxidative stress through the enhancement of antioxidant enzymes 
and the decrease of cytochrome P450 system activity.[35] Diallyl 
trisulfide from garlic has also been found to play protective roles 
in CCl4‑induced acute liver damage.
[36] This result is consistent 
with our findings that aged garlic derived S‑allylmercaptocyste‑
ine (SAMC) alleviated CCl4‑induced hepatic necro‑inflammation 
and oxidative stress. SAMC also promoted liver regenerative 
ability after acute injury.[37] Thus, based on these observations, 
we evaluated the protective property of SAMC against NAFLD 
in our clinically relevant high‑fat diet model. Similar to the results 
of LBP, our high‑fat diet recipe induced evident NAFLD symp‑
toms in rats after an 8‑week feeding. SAMC co‑treatment also 
potently attenuated NAFLD features including steatosis, fibrosis, 
oxidative stress, and inflammation. These beneficial effects were 
partially mediated by kinase‑ and transcriptional factor‑dependent 
pathways.[38] In addition, we demonstrated that SAMC could also 
inhibit apoptosis while promoting hepatic macroautophagy, con‑
tributing to further protection against NAFLD‑induced chronic 
liver injury (Xiao et al., article in press).
Green tea (綠茶 Lǜ Chá)
Green tea is one of the best documented plants that have been 
used in the prevention of liver diseases. It has also received much 
attention in the last 20 years. Green tea is a kind of tea made solely 
from the leaves of plant Camellia sinensis. It originated from China 
and then spread to other Asian countries, such as Japan, Korea, and 
Vietnam. Recently, it has also spread to Western countries where 
black tea is traditionally consumed. Studies using extracts from 
green tea found the beneficial or even therapeutic effects of green 
tea on liver diseases. Chen et al., used a pure form of epigallocate‑
chin‑3‑gallate (EGCG), the major polyphenol of green tea, in mice 
treated with CCl4. They found that EGCG showed a dose‑dependent 
ameliorative effect on CCl4‑induced liver injury, oxidative stress, 
and inflammation at both histological and biochemical levels.[39] An‑
other recent study demonstrated that EGCG potently inhibited the 
entry of hepatitis C virus (HCV) in hepatoma cell lines and primary 
human hepatocytes through blocking both extracellular virions and 
cell‑to‑cell spread.[40] In alcohol‑induced rat liver injury model, 
co‑treatment of whole green tea extracts with ethanol administration 
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effectively attenuated hepatic oxidative stress through cytochrome 
P450 2E1 (CYP2E1) and reduced form of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase systems.[41] Moreover, 
in obese mice, typical NASH features, including lipid accumula‑
tion, oxidative stress, nitrative stress, and inflammatory response, 
were attenuated by green tea extract administration.[42] Our recent 
study suggested that 85% pure extract of (−) EGCG reduced the 
severity of liver injury in an experimental model of NAFLD associ‑
ated with lower concentration of pro‑fibrogenic, oxidative stress, 
and pro‑inflammatory mediators, partly through modulating the 
activities of transforming growth factor/SMAD (TGF/SMAD), 
phosphoinositide 3‑kinase/Akt/forkhead box protein O1 (PI3K/Akt/
FoxO1) and NF‑κB pathways. Therefore, green tea polyphenols and 
EGCG are a useful supplement in the prevention of NAFLD (Xiao 
et al., submitted manuscript).
Resveratrol
Resveratrol (RSV; 3,5,4′‑trihydroxystilbene) is a phytoalexin 
extracted from red grapes. It is one of the most well‑documented 
and accepted herbal derivatives in the world due to its strong 
capacity against oxidation and inflammation.[43] In recent years, 
many groups have found the very promising phytochemical proper‑
ties of RSV in the treatment of NAFLD. Co‑treatment with RSV 
promoted the phosphorylation of AMPK, leading to the suppres‑
sion of lipogenic genes (SREBP‑1c and FAS), after NAFLD was 
induced with high‑fat diet.[44] This effect was further supported by 
the studies that followed in which treatment of RSV attenuated 
oxidative stress and inflammation in vivo.[45] The effects of RSV 
on dysregulated lipid metabolism during NAFLD were found to 
be through sirtuin 1 (SIRT1) pathway[46,47] and the up‑regulation 
of hepatic low‑density lipoprotein receptor.[48] Regarding its potent 
effects on oxidative stress and inflammation, as well as its wide 
availability around the world, RSV is a significant candidate for 
the daily prevention of fatty liver diseases.
Milk thistles
Both silybin and silymarin are derivatives of plant milk 
thistle (Silybum marianum), a flowering plant of the daisy 
family. In the past 10 years, more than 10,000 papers have 
been published on the antioxidative, chemopreventive, and 
hepatoprotective effects of these substances. In the liver cells, 
the common beneficial effects of silybin and silymarin include 
antioxidative effects, direct/indirect effects on inflammation and 
fibrosis, as well as modulation of metabolic pathways. For ex‑
ample, in the presence of oxidative stress and nitrosative stress, 
silybin inhibits the formation of free radicals and nitric oxide, 
phosphorylates adenosine diphosphate to increase the content 
of adenosine triphosphate, decreases the content of MDA, and 
recovers the basal expression levels of antioxidant enzymes such 
as catalase (CAT), superoxide dismutase (SOD), and glutathione 
peroxidase (GPx).[49,50] The anti‑inflammatory effects of silybin 
and silymarin are from their interference with NF‑κB–controlled 
transduction cascade. Consistent with the antioxidant activity, 
silybin and silymarin inhibit NF‑κB activation and translocation 
through suppression of upstream phosphorylation and degradation 
of IκBα.[51] A recent basic study exhibited that crude extract of 
Silybum marianum played anti‑apoptotic and anti‑inflammatory 
roles in the treatment of experimental steatohepatitis, when rats 
were fed with methionine and choline deficient (MCD) diet for 
8 weeks. The beneficial effects of S. marianum were partly found 
to be through the mitogen‑activated protein kinase (MAPK) 
pathway.[52] Another interesting clinical study found that when 
compared with the therapeutic effects on chronic hepatitis C 
patients, the effects of silymarin were better on NAFLD patients 
due to their higher flavonolignan plasma concentrations and more 
extensive enterohepatic cycling.[53]
Other derivatives and decoctions
Unlike the modern Western medicine, traditional Chinese 
medicine prefers herbology, meaning the combination of dif‑
ferent medical herbs into one recipe or prescription.[54] With the 
help from advanced technologies in chemistry, pharmacology, 
and experimental biology, the effective monomers of many 
Chinese medicine formulae have been identified. One of the 
most attractive monomers is berberine, an alkaloid isolated 
from the Chinese herb Coptidis rhizoma (黃連 Huáng Lián, 
the root of Coptis chinensis). In laboratory studies, berberine is 
considered to possess an anti‑steatotic effect due to its ability to 
re‑activate AMPK[55] and to up‑regulate low‑density lipoprotein 
receptor expression through the extracellular signal‑regulated 
kinase (ERK) and c‑Jun N‑terminal kinase (JNK) pathways.[56,57] 
In addition, berberine is shown to reduce hepatic inflammatory 
responses. In db/db mice, addition of berberine down‑regulated 
the expression of pro‑inflammatory cytokines [e.g. tumor necro‑
sis factor (TNF)‑α and interleukin (IL)‑6] through the modula‑
tion of NF‑κB signaling pathway.[55,58] However, to date, there 
is no direct study examining the effects of berberine treatment 
on NAFLD.
In the therapy of Chinese medicine, herbal prescriptions of 
NAFLD are formulated from several kinds of herbs, based on 
the symptoms of patients. So, it is relatively difficult to figure out 
which component from the formula is the main effective monomer 
for the therapy of NAFLD. Actually, under most circumstances, 
the therapeutic properties of herbal formulae largely depend on the 
additive or synergistic effects of these monomers. In recent years, 
the functions of several Chinese medicine formulae in NAFLD 
treatment have been investigated in both pre‑clinical and clinical 
studies. This aspect of information has been well reviewed by 
Dong et al.[59]
PERSPECTIVES AND FUTURE DIRECTIONS
Since the pathogenesis of NAFLD is attributed to multiple 
and parallel levels of pathological events, from upstream insulin 
resistance to downstream apoptosis/autophagy, effective thera‑
pies for NAFLD should target one or several of these events. To 
date, LBP, garlic derivatives, green tea, resveratrol, and milk 
thistle derivatives are the most promising reagents that can 
target most of the pathological changes during NAFLD devel‑
opment. Some of them even have clinical trial data to support 
their possible therapeutic function for NAFLD (e.g. LBP and 
milk thistle). The detailed experimental achievements of these 
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derivatives are summarized in Table 1. The major problems 
in the widespread use of these derivatives are the shortage 
of detailed mechanistic pre‑clinical studies and clinical trials 
evaluating their long‑term side effects. Indeed, isolation of more 
potent anti‑NAFLD monomers or Chinese medicine formulae 
is also necessary to effectively use these herbal agents in the 
Table 1. Summary of the beneficial properties of common herbal derivatives against NAFLD‑induced hepatic injury from recent studies




30‑day randomized, double‑blind, 
placebo‑controlled clinical study in 
aged Chinese
Daily 120 ml 
LBP‑standardized L. barbarum 
preparation (GoChi) drink
Increased serum levels of 
antioxidants (SOD and GSH‑Px) 
and decreased lipid peroxidation
[25]
Increased number of lymphocytes 
and levels of interleukin‑2 and 
immunoglobulin G
[26]
Two‑month induction of NAFLD 
with high‑fat diet in Kunming mice
Daily oral feeding with 
50 mg/kg, 100 mg/kg, and 
150 mg/kg LBP
Increased blood and hepatic 
antioxidant levels (e.g. SOD, 
GSH‑Px, and CAT) and decreased 
MDA formation
[29]
Eight‑week induction of NAFLD 
using a voluntary high‑fat diet 
model (30% fat) in SD rats
Daily oral feeding with 
1 mg/kg LBP
Improved histology, fibrosis, 
oxidative stress, inflammation, 
and apoptosis through kinase‑and 
transcription factor‑mediated 
pathways
Xiao et al., 
submitted 
manuscript
Garlic Eight‑week induction of NAFLD 
using a high‑fat diet model 
(45% fat) in C57BL/6J mice
Another 7‑week feeding with 
high‑fat diets supplemented 
with 2% or 5% garlic (wt:wt)
Reduced body weight, white 
adipose tissue deposits, and 
hepatic lipid accumulation 
through AMPK pathway
[33]
Eight‑week induction of NAFLD 
using a 65% fructose diet in SD rats
Daily oral feeding with raw 
garlic homogenate (250 mg/kg)
Improved insulin and glucose 
metabolism; reduced lipid 
deposition and oxidative stress
[34]
Eight‑week induction of NAFLD 
using a voluntary high‑fat diet 
model (30% fat) in SD rats
Intraperitoneal injection of 
200 mg/kg garlic‑derived 
SAMC 3 times a week
Improved steatosis, fibrosis, 
oxidative stress, and inflammation 
through kinase‑and transcription 
factor‑mediated pathways
[38]
Green tea Leptin‑deficient obese (ob/ob) mice Daily feeding with AIN‑93G 
diet containing green tea 
extracts at 0.5% or 1% (wt/wt)
Reduced lipid accumulation, 
inflammation, oxidative stress, 
and nitrative stress
[42]
Eight‑week induction of NAFLD 
using a voluntary high‑fat diet 
model (30% fat) in SD rats
Intraperitoneal injection of 
50 mg/kg green tea–derived 
EGCG 3 times a week
Reduced steatosis, fibrosis, 
necrosis, and inflammation 
through TGF/SMAD, PI3K/Akt/
FoxO1, and NF‑kappa B pathways
[38]
Resveratrol Sixteen‑week induction of NAFLD 
with high‑fat diet (59% fat) in 
Wistar rats
Daily oral feeding with 
resveratrol (100 mg/kg) from 
week 11 to week 16
Reduced hepatic triglyceride 
accumulation and insulin 
resistance partly through AMPK
[44]
Four‑week induction of NAFLD 
with high‑carbohydrate diet (80% 
carbohydrate)
Daily oral feeding with 10 mg 
resveratrol
Reduced steatosis, oxidative 
stress, glucose level, and 
inflammation
[45]
Thirteen‑week induction of NAFLD 
with high‑fat diet (54% fat) in 
Wistar rats
Daily oral feeding with 50 mg 
or 100 mg/kg resveratrol
Reduced steatosis with 
up‑regulation of hepatic 
low‑density lipoprotein receptor 
and scavenger receptor class B 
type I gene expressions
[48]
Steatosis was induced by incubating 
HepG2 cells with 0.05‑0.3 mM 
palmitate
Co‑incubation with 40 μM 
resveratrol
Reduced steatosis through SIRT1‑
FoxO1 pathway
[47]
Milk thistle Eleven‑week induction of NAFLD 
using an MCD model in N‑Mary rats
Equivalent to 1.0 g seeds 
powder/kg body weight/day by 
gavage
Alleviated inflammation, oxidative 
stress, and apoptosis through 
kinase‑dependent pathways
[52]
Patients with NAFLD Oral silymarin (280 or 560 mg) 
every 8 h for 7 days
Effects of silymarin were better 
on NAFLD patients than HCV 
patients
[53]
NAFLD: non‑alcoholic fatty liver disease; SD: Sprague‑Dawley; MCD: methionine and choline deficient; LBP: Lycium barbarum ploysaccharide; SAMC: 
S‑allylmercaptocysteine; SOD: superoxide dismutase; GSH‑Px: glutathione peroxidase; CAT: catalase; MDA: malondialdehyde; AMPK: AMP‑activated 
protein kinase; TGF: transforming growth factor; HCV: hepatitis C virus
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daily prevention and therapy of chronic liver diseases and other 
related metabolic syndromes.
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